13th week of 2016 patent applcation highlights part 7 |
Patent application number | Title | Published |
20160089390 | Use of MicroRNA or Inhibitors Thereof in Regulation of Lipid Metabolism - The present invention relates to use of a microRNA or an inhibitor thereof, and specifically, the present invention relates to use of a microRNA or an inhibitor thereof in preparing a medicament for regulating lipid metabolism or preparing a medicament for preventing or treating a disease related to lipid metabolism. The microRNA is one or more of the following: miRNA-96, miRNA-185, and miRNA-223. The present invention also relates to use of the microRNA or the inhibitor thereof in regulating the expression level of a protein related to lipid metabolism. The present invention also relates to a composition comprising the microRNA or the inhibitor thereof. The microRNA or the inhibitor thereof in the present invention can be used as a pharmaceutical component, and can be applied in preventing or treating a disease caused by lipid metabolism disorders such as hyperlipidemia, atherosclerosis, coronary heart disease or other diseases. | 2016-03-31 |
20160089391 | Molecular Targets for Cardiovascular Disease - The invention relates to methods and compositions for treating and preventing cardiovascular disease, including but not limited to treating and preventing endothelial dysfunction in subjects having hyperhomocysteinemia, hyperglycemia, or a combination of hyperhomocysteinemia and hyperglycemia. As endothelial dysfunction is an indicator for atherosclerosis and cardiovascular disease, this treatment has general impact for early prevention and treatment for all cardiovascular disease. In particular, the present invention relates to methods and compositions for inhibiting calpain activity. | 2016-03-31 |
20160089392 | Whey Protein and Resistant Starch Compositions to Reduce Body Mass Index - A nutritional composition comprised of whey protein (WP) and resistant starch (RS) designed to reduce body fat, body fat distribution and as a result lower Body Mass Index (BMI) in humans. | 2016-03-31 |
20160089393 | COMPOSITION AND METHODS FOR COMBATING ANTIBACTERIAL RESISTANT BACTERIA - The present invention provides compositions and methods for sensitizing a bacterium to an antibacterial the method comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance. Methods for killing an antibacterial-resistant bacterium comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance and exposing the bacterium to an antibacterial are also provided. The methods may also include the step of identifying the bacterium and the antibacterial resistance profile of the bacterium and tailoring the methods accordingly. Exemplary entry promoting agents provided are polyhexamethylene biguanide (PHMB) and polyhexamethyleneguanide (PHMG). Exemplary agents that inhibit antibacterial resistance are agents that bindto and inhibit antibacterial-resistance determinants such as beta-lactamases, PBP2a, NDM-1 and Vim2. Compositions, pharmaceutical compositions/formulations and medical uses thereof are also provided according to the invention. | 2016-03-31 |
20160089394 | METHOD AND DEVICE FOR PRODUCING HYDROGEN CONTAINING FLUID - A device for producing a hydrogen containing fluid, having a container that stores fluid which able to be used for a living organism and has water vapor permeability, a hydrogen generating system that generates hydrogen by using moisture, and a wrapping member that encloses the container and the hydrogen generating system and has low hydrogen molecule permeability. The wrapping member encloses the container and the hydrogen generating system located outside the container, and a treatment to increase humidity in a space between an outer surface of the container and an inner surface of the wrapping member is performed. | 2016-03-31 |
20160089395 | COMPOSITIONS AND METHODS FOR ALTERING HUMAN CUTANEOUS MICROBIOME TO INCREASE GROWTH OF STAPHYLOCOCCUS EPIDERMIDIS AND REDUCE STAPHYLOCOCCUS AUREUS PROLIFERATION - An antibacterial composition comprising arginine bicarbonate, zinc carbonate, preferably arginine bicarbonate and zinc carbonate (ABZC), in combination, plus one or more physiologically acceptable excipients, administered for the modification of cutaneous microfloras, generally to inhibit the growth of pathogenic | 2016-03-31 |
20160089396 | METHODS AND COMPOSITIONS FOR REGULATING BIOFILM DEVELOPMENT - The present invention relates to methods for promoting dispersal of, or preventing formation of microbial biofilms, comprising: exposing a biofilm to an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; treating a surface or medium susceptible to biofilm formation with an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; incorporating an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent in a surface or medium susceptible to biofilm formation; or inducing the accumulation of one or more reactive oxygen or nitrogen species within microorganisms within said biofilm or capable of forming a biofilm. The invention also relates to methods for maintaining or enhancing or maintaining and enhancing the functioning of a biofilm, comprising exposing a biofilm to at least one nitric oxide scavenger, at least one antioxidant or at least one nitric oxide scavenger and at least one antioxidant. The invention also relates to compositions for promoting dispersal of, or preventing formation of microbial biofilms, or for maintaining or enhancing or maintaining and enhancing the functioning of microbial biofilms. | 2016-03-31 |
20160089397 | CORRELATES OF EFFICACY RELATING TO TUMOR VACCINES - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through a combination of ex vivo gene therapy protocols and cell enchment, tumor cells are engineered to express an α (1,3)galactosyl epitope and optionally the tumor associated antigens mesothelin and carcinoembryonic antigen. After administration of the compositions of the invention to patients, the production of increased antibody titers to certain cell-surface markers, including mesothelin, calreticulin, and carcinembryonic antigen (CEA) positively correlates with an increased overall survival. | 2016-03-31 |
20160089398 | Engineered Cells Expressing Multiple Immunomodulators and Uses Thereof - This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. | 2016-03-31 |
20160089399 | NON-HEMOLYZING BLOOD FILTER AND METHODS FOR FILTERING BLOOD WITHOUT HEMOLYSIS - An article, system, and method is provided for the filtration of blood wherein the blood is removed, contacted with a filter substrate operatively associated with a filter structure, and the filtered blood is subsequently returned to a receiver. Methods for removing iron from the liquid fraction of blood and for determining whether a substrate is capable of selectively retaining 2,2′-dipyrydyl (DP)-Fe | 2016-03-31 |
20160089400 | FERMENTED NUTRITIONAL COMPOSITION WITH THIOL PROTEASE INHIBITOR - The present invention relates to fermentation of milk-derived nutritional compositions to increase thiol protease inhibitor activity, and uses thereof with the products obtained. | 2016-03-31 |
20160089401 | USES OF TREHALOSE IN CELL SUSPENSIONS - Disclosed are cellular compositions and methods relating to the use of aqueous trehalose media to suspend cells. A trehalose-containing medium can be used to inhibit cellular clumping, for example upon dilution of more concentrated cellular preparations into the trehalose-containing medium. In certain embodiments cells, after cryopreservation and thawing, are combined with a trehalose-containing medium to prepare a clumping-inhibited cell suspension. | 2016-03-31 |
20160089402 | EXTRACT, AND PREPARATION CONTAINING SAID EXTRACT - An object of the present invention is to provide an extract from inflamed skins of rabbits inoculated with vaccinia virus where the quality of the extract is more stabilized and also to provide a preparation, etc. containing said extract as an active ingredient. | 2016-03-31 |
20160089403 | TREATMENT OF ATOPIC DERMATITIS AND INFECTIOUS DERMATITIS WITH BIOLOGICAL SPA THERAPY - Provided is a method for treatment of atopic dermatitis and infectious dermatitis with biological spa therapy. The method seeks to cure or alleviate symptoms of atopic dermatitis by bathing in a bathwater containing, as dominant bacteria, not less than 10 | 2016-03-31 |
20160089404 | LACHNOSPIRACEAE IN THE GUT MICROBIOTA AND ASSOCIATION WITH BODY WEIGHT - The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. | 2016-03-31 |
20160089405 | Treatment and Prophylaxis for Gastroesophageal Reflux Disease - An embodiment is a method of preventing, mitigating or treating Gastroesophageal Reflux Disease (GERD) that includes administering an effective amount of a medicament comprised of the | 2016-03-31 |
20160089406 | CEREAL CONTAINING HERICIUM ERINACEUM AND METHOD FOR MAKING SAME - The present invention relates to a | 2016-03-31 |
20160089407 | USE OF TALL OIL FATTY ACID - The present invention relates to use of a tall oil fatty acid in enhancing rumen fermentation and/or lowering rumen methane production. The invention further relates to use of a feed supplement and a feed composition comprising tall oil fatty acid | 2016-03-31 |
20160089408 | FERMENTED FOOD IMPROVING BOWEL FUNCTIONS WITH STERCORAL REMOVAL EFFICIENCY AND MANUFACTURING METHOD THEREOF - Exemplary embodiments of the present invention provide fermented foods improving bowel functions with stercoral removal efficiency and a manufacturing method thereof. The manufacturing method of the fermented foods improving bowel functions includes a first process in which herb powder and glasswort powder placed in a cloth pouch together are heated in a potable water, and a second process in which the previously heated mixture is fermented at 20-50° C. with fermenting strain. In a third process, the previously fermented mixture may be solidified then kneaded with | 2016-03-31 |
20160089409 | A METHOD AND COMPOSITION USING PARSLEY (PETROSELINUM CRISPUM) AS A NATURAL REMEDY FOR DIABETES MELLITUS - A homogenate to be administered to a patient to inhibit and reduce increased glucose level in the blood and stimulate insulin secretion. The homogenate includes the use of different components, mainly the herb | 2016-03-31 |
20160089410 | COMPOSITION FOR NOURISHING INJURED HUMAN TROPHOBLAST CELLS AND INHIBITING APOPTOSIS THEREIN - Composition useful in treating and/or preventing spontaneous abortions derived from a traditional recipe of herbal medicine. The composition contains active components from three herbal medicines: total flavonoids of | 2016-03-31 |
20160089411 | METHOD AND COMPOSITION FOR TREATING SYMPTOMS OF SICKLE CELL DISEASE - Disclosed herein is a nutraceutical composition comprising dried | 2016-03-31 |
20160089412 | REMEDIAL TONIC - A medicinal tonic has a unique combination of ingredients. The tonic is composed, proportionally, of approximately 66 fluid ounces of organic Aloe juice, 60 ounces of organic Aloe gel, 16 grams be weight of wild lapacho bark extract, and 20 milliliters each of organic hyssop, organic or wild milk thistle extract and organic, naturally farmed olive leaf extract. The ingredients produce a new and medicinal compound that prevents or alleviates natural occurring diseases or conditions and helps heal wounds and other ailments and has other salutary effects on the human body. | 2016-03-31 |
20160089413 | USE OF CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY FOR THE TREATMENT OF CHRONIC OR NON-CHRONIC INFLAMMATORY EYE DISEASES - The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scieritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc. | 2016-03-31 |
20160089414 | NOVEL INHIBITORS OF NOX1 - The present invention relates to inhibitors of Nox1-dependent reactive oxygen species production and their use in the treatment of disorders associated with reactive oxygen species, such as hypertension and cancer. | 2016-03-31 |
20160089415 | ELASTIN PROTECTIVE POLYPHENOLICS AND METHODS OF USING THE SAME - Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra- tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers. | 2016-03-31 |
20160089416 | METHOD OF TREATING CANCER - This disclosure pertains to a method of treating liver cancer using a peptide based on venom from a | 2016-03-31 |
20160089417 | TREATING LIVER DISEASES - This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided. | 2016-03-31 |
20160089418 | THERAPEUTIC COMPOSITIONS FOR NEUTRALIZING TYPE I INTERFERONS, AND METHODS OF USE - The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence. | 2016-03-31 |
20160089419 | Method for Bowel Preparation - The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty. | 2016-03-31 |
20160089420 | ACTIVATED LEUKOCYTE CONDITIONED SUPERNATANT AND USES FOR WOUND HEALING - Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds. | 2016-03-31 |
20160089421 | STEM CELLS FOR TRANSPLANTATION AND MANUFACTURING METHOD THEREFOR - It is intended to provide MSCs for transplantation that have an improved post-transplantation cell survival rate and engraftment rate and are highly safe with fewer adverse reactions, and a method for conveniently producing MSCs for transplantation having a high cell survival rate and engraftment rate. As means therefor, the present invention provides a stem cell for transplantation comprising an MSC capable of overexpressing IL-10. | 2016-03-31 |
20160089422 | METHOD FOR INACTIVATING A PRION PROTEIN - The invention relates to a process for inactivating pathological prion proteins (PrPsc) in a sample or a material which may be contaminated by a pathological prion protein, wherein the sample or the material which may be contaminated by a pathological prion protein is put into contact with at least one methionine sulfoxide reductase. | 2016-03-31 |
20160089423 | COMPOSITIONS AND METHODS FOR TREATING POST-OPERATIVE COMPLICATIONS OF CARDIOPULMONARY SURGERY - Disclosed herein are compositions and methods for treating damage inflicted by use of a cardio-pulmonary bypass (CPB) machine, particularly excessive bleeding and multi organ failure, by administering a pharmaceutical composition comprising alpha-1 antitrypsin (AAT). | 2016-03-31 |
20160089424 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 2016-03-31 |
20160089425 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 2016-03-31 |
20160089426 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 2016-03-31 |
20160089427 | Genetically Modified Yersinia as Vaccines Against Yersinia Species - Recombinant attenuated | 2016-03-31 |
20160089428 | PHARMACEUTICAL PREPARATION COMPRISING A COMBINATION OF STREPTOCOCCUS STRAINS AND LACTOBACILLUS STRAINS - A pharmaceutical preparation for prophylaxis against and treatment of | 2016-03-31 |
20160089429 | ORAL VACCINE HAVING IMPROVED CELLULAR IMMUNITY INDUCTION POTENCY - An oral preparation for the prophylaxis or treatment of a disease with infection by a pathogen, containing a killed lactic acid bacterium expressing, on the surface, an antigen of the pathogen, or a microparticulated form thereof, which has an average particle size of 2.68-30 μm. An oral preparation for inducing cellular immunity to a target antigen, containing a killed lactic acid bacterium expressing the target antigen on the surface or a microparticulated form thereof, which has a particle size of 2.68-30 μm. | 2016-03-31 |
20160089430 | COMPOSITIONS CONTAINING AMBIENT-TEMPERATURE STABLE, INACTIVATED BUT THERAPEUTICALLY ACTIVE BIOPHARMACEUTICALS & METHODS FOR FORMULATION THEREOF - The disclosure concerns compositions containing inactivated but therapeutically active biopharmaceuticals, and methods for formulation thereof. Biopharmaceuticals are encapsulated and immobilized in dry amorphous carbohydrate-glass and irradiated for inactivation while in the dry state. The resulting compositions provide ambient-temperature stable, therapeutically active but inactivated biopharmaceuticals for use in vaccines and other applications. | 2016-03-31 |
20160089431 | Nanodisk-associated immunogen super polyvalent vaccines - Disclosed are compositions of matter consisting of collections of nanodisks associated with polypeptide immunogens. Each said collection contains multiple epitopes of at least one immunogen. When used as a component of a vaccine, these epitopes are chosen to confer immunity, in the vaccinated subject, against a spectrum of possible infective strains of the target pathogen. This immunity is derived from the various antibodies, to the various epitopes of the immunogen, produced by the adaptive immune system of the subject in response to exposure to said vaccine. In this manner, said vaccine may confer immunity against the entire spectrum of possible infective strains of the target pathogen. | 2016-03-31 |
20160089432 | METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION - Compositions, vaccines and methods for inducing protective immunity against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of HIV. | 2016-03-31 |
20160089433 | Induction of IL-12 using immunotherapy - The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity. | 2016-03-31 |
20160089434 | COMBINATIONS OF AN ANTI-PD-L1 ANTIBODY AND A MEK INHIBITOR AND/OR A BRAF INHIBITOR - A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and/or a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and an anti-PD-L1 antibody; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or neutralizing or inhibiting the interaction between PD-L1 and its receptor, e.g. PD-1, is beneficial, eg. cancer. | 2016-03-31 |
20160089435 | PAN-HER ANTIBODY COMPOSITION - The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor. | 2016-03-31 |
20160089436 | SELF-ASSEMBLED PHARMACEUTICAL COMPOSITION FOR PHOTODYNAMIC THERAPY - The present invention relates to a nanoformulated self-assembled pharmaceutical composition for photodynamic therapy. More particularly, the present invention is directed to a self-assembled pharmaceutical composition for photodynamic therapy comprising a photosensitizer, a ligand A which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range and a method for manufacturing the same. | 2016-03-31 |
20160089437 | FLOCCULATED MEGESTROL ACETATE SUSPENSION - The present invention relates to a novel oral pharmaceutical composition in the form of a stable flocculated suspension in water, said composition comprising micronized megestrol acetate at a concentration of 10 to 200 mg per ml, polysorbate at a concentration of 0.01% to 12.6% weight by volume, or polyethylene glycol at a concentration of about 0.01% to 5.0% weight by volume, polyoxyl 35 castor oil at a concentration of 0.05% to 51.5% weight by volume and/or polyoxyl 40 hydrogenated castor oil at a concentration of 0.05% to 45% weight by volume in a stable flocculated suspension in water. The composition also may include preservatives, sweeteners, pH adjusting agents and flavoring agents. | 2016-03-31 |
20160089438 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 2016-03-31 |
20160089440 | POTENCY-EXTENDING AGENT OF BOTULINUM TOXIN TYPE-A PRODUCT - A potency-extending agent of a botulinum toxin type-A product includes 1 ml of distilled water, 85 of dextrose, 4.28 mg of sodium chloride, and 10 mg of trehalose. | 2016-03-31 |
20160089441 | COMPOSITION FOR THE TREATMENT OF COLD SORES - A composition used in the treatment of the cold sores is composed of Water, Propylene Glycol, Mineral Oil, Behenyl Alcohol or docosanol, Benzocaine, Vitamin E tocopheryl, Sucrose Stearate, and Benzyl Alcohol. | 2016-03-31 |
20160089442 | Lyophilized Preparation of Botulinum Toxin - There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed. | 2016-03-31 |
20160089443 | PROTEIN-GRAPHENE NANOCOMPOSITE DRUG CARRIER - A drug carrier includes an aqueous solution, a protein shell, graphenes, and a bioactive agent. The protein shell encloses the aqueous solution, and includes at least one hydrophilic/hydrophobic layer. The graphenes are dispersed in the protein shell, and the bioactive agent is in the aqueous solution and/or the protein shell. | 2016-03-31 |
20160089444 | MATERIALS FOR MODULATING BIOLOGICAL RESPONSES AND METHODS OF MAKING - A polymeric composition capable of releasing nitric oxide and modulating biological responses comprises a biocompatible polymer and S-nitrosated thiol bonded to the biocompatible polymer. The polymeric composition can have a thiol conversion of at least 40%. The polymeric composition can also have a nitric oxide recovery of at least 40% when under thermal decomposition conditions. | 2016-03-31 |
20160089445 | DERIVATISATION OF BIOLOGICAL MOLECULES - The present disclosure relates to a new polymerisation process in which ethylenically unsaturated monomers are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula | 2016-03-31 |
20160089446 | Modified Hydrogels - The present invention relates to a process for the preparation of a hydrogel suitable as carrier in a hydrogel-linked prodrug, to hydrogels obtainable from said process, the use of such hydrogel as a carrier in a hydrogel-linked prodrug and to hydrogel-linked prodrugs comprising a covalently conjugated hydrogel of the present invention. The hydrogel prodrug carrier has a reduced drug loading on the outside of the hydrogel carrier. This is achieved by reducing the number of functional groups of the hydrogel, in particular those at its surface. | 2016-03-31 |
20160089447 | Cell Penetrating Peptides for Intracellular Delivery of Molecules - A cell-penetrating peptide characterized in that it comprises an amino acid sequence X | 2016-03-31 |
20160089448 | POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER - A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier. | 2016-03-31 |
20160089449 | Dock-and-Lock (DNL) Constructs for Human Immunodeficiency Virus (HIV) Therapy - The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents. | 2016-03-31 |
20160089450 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY - The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer. | 2016-03-31 |
20160089451 | METHODS AND COMPOSITIONS FOR TREATMENT OF FORBES-CORI DISEASE - In certain embodiments, the present disclosure provides compositions and methods for treating Forbes-Cori Disease. | 2016-03-31 |
20160089452 | MAGNETIC CELLS FOR LOCALIZING DELIVERY AND TISSUE REPAIR - Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. For treatment of disease and/or injury. | 2016-03-31 |
20160089453 | RNA-MODULATING AGENTS - The instant disclosure provides RNA-modulating agents that function to recruit one or more small regulatoryRNA molecules (e.g., miRNA molecules, Y RNAs, and siRNAs) to a target mRNA thereby modulating (e.g., inhibiting) the translation of the target mRNA or destabilizing the mRNA. Also provided are miRNA inhibitors and diagnostic agents that have improved binding affinity for their target miRNAs. Methods for using the RNA-modulating agents, miRNA inhibitors and diagnostic agents are also provided. | 2016-03-31 |
20160089454 | GEL FORMULATIONS FOR GUIDING RADIOTHERAPY - The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body. | 2016-03-31 |
20160089455 | MRI CONTRASTING AGENT FOR CONTRASTING CANCER CELL - The present invention relates to MRI contrasting agent for contrasting cancer cell which contains ultrafine nanoparticles. More particularly, the present invention is directed to a self-assembled ligand composition comprising a ligand A, which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range, MRI contrast agent for contrasting cancer cell comprising said ligand composition and MRI contrasting nanoparticles, and the methods for preparing them. | 2016-03-31 |
20160089456 | METHODS DEVICES AND SYSTEMS OF PREPARING TARGETED MICROBUBBLE SHELLS - Targeted microbubbles are generated by post-labeling buried ligand microbubbles. According to embodiments, buried ligand microbubbles are created with steric brushes protecting functionalized polymer tethers. Ligands were attached to the functionalized tethers by diffusion of ligands of a small size through the steric barrier. The steric barrier was substantially capable of hindering access to the tethers by larger molecules. The embodiments disclosed include methods for creating microbubble batches that can be loaded with selected ligands, for titrating the targeting ligands thereby to reduce waste and cost, and for using resulting buried ligand molecules for medical purposes. | 2016-03-31 |
20160089457 | ULTRAVIOLET LIGHT SOURCE AND METHODS - A UV device includes a housing having a portion configured to be removably attached to a smart device, a UV light source disposed within the housing, wherein the UV light source is configured to provide output of UV light in response to an operating powered, a communication mechanism disposed within the housing, wherein the communication mechanism is configured to receive instructions from the smart device, a control mechanism disposed within the housing, wherein the control mechanism is coupled to the UV light source, and to the communication mechanism, wherein the control mechanism is configured to provide the operating power to the UV light source, in response to the instructions received from the smart device. | 2016-03-31 |
20160089458 | ULTRAVIOLET LIGHT SOURCE AND METHODS - A method for a smart-device comprising receiving a user selection of an icon on a display, initiating acquisition of a first image of a target surface using a camera in response to receiving the selection, directing power to an UV-LED disposed proximate to the camera, wherein the power is provided to the UV-LEDs for less than about 0.5 seconds, while power is provided to the UV-LED, initiating acquisition of a second image of a target surface using the camera, determining an image visually highlighting a contaminant on the target surface in response to the first and second images, determining an object type associated with the target surface, in response to the first image, determining geographic data, and storing the image, the object type, and the geographic data in a memory. | 2016-03-31 |
20160089459 | SYSTEMS AND METHODS FOR TREATMENT OF CABIN SURFACES AND AIR - Embodiments relate generally to systems and methods for treating passenger transportation vehicle cabin surfaces and surrounding air. The methods may use organic LEDs to produce ultraviolet light. Systems may be provided to ensure safety and operation of the air treatment only when passengers and personnel are not present in the cabin. | 2016-03-31 |
20160089460 | DETERGENT POURER STERILIZER AND STERILIZING METHOD THEREBY - Disclosed herein is a detergent pourer sterilizer. In one aspect, a detergent pourer sterilizer is provided to include a housing including a hollow portion having an open side; a detergent pourer configured to be detachably attached to the housing; a cover member configured to open or close the one open side of the hollow portion; and at least one UV LED configured to emit ultraviolet light toward the hollow portion. | 2016-03-31 |
20160089461 | SANITIZING DEVICE - The shoe sole sanitizer provides a UV radiation emitting system that kills microbial pathogens deposited on shoe sole surfaces. The system includes a housing containing at least one UV radiation source. Bottom and side portions of the housing are opaque to provide a UV shield while directing the UV upward towards a top housing portion. The top housing portion has a plurality of holes forming an approximate shape of two shoe sole bottoms. The holes allow the UV radiation to escape the housing and target sole surfaces disposed on and over the exterior of the housing top. Each shoe sole approximation area has a pivotal tang that extends therefrom. Shutters attached internally to the tangs extend or limit UV exposure from the top surface depending on the size of the sole disposed on the top. The system is powered by standard AC electrical power or battery sources. | 2016-03-31 |
20160089462 | FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME - The present invention relates to freshening compositions and devices comprising same that comprise a composition having a viscosity of from about 1 mPa·s to about 50,000 mPa·s comprising malodor reduction compositions and methods of making and using such compositions. The disclosed malodor reduction compositions do not unduely interfere with the scent of the freshening compositions and devices that comprise such technologies and the perfumed or unperfumed situs that is treated with such freshening compositions and devices. | 2016-03-31 |
20160089463 | METHOD AND SYSTEM FOR CLEANING AND SANITIZING CONVEY LINES - A sanitization system for sanitizing a convey line broadly includes an ozone generation and delivery module, a compressed air source, and an air flow control system, and an ozone measurement and destruction module. The ozone generation and delivery module includes ozone generator, an ozone flow meter, a first ozone analyzer, a humidifier, and a humidity sensor and introduces a measured ozone gas stream into the convey line so that the ozone disinfects the inner surfaces of the convey line. The humidifier introduces moisture into the convey line to increase the effectiveness of the ozone as a disinfection agent. The ozone measurement and destruction module includes a second ozone analyzer, an ozone destructor, and an ozone monitor and removes ozone from the gas stream. The ozone measurement and destruction module also ensures that a desired amount of ozone reaches the end of the convey line. | 2016-03-31 |
20160089464 | MALODOR REDUCTION COMPOSITIONS - The present invention relates to malodor reduction compositions and methods of making and using same. The malodor reduction compositions are suitable for use in a variety of applications, including use in consumer products, for example, air freshening compositions, laundry detergents, fabric enhancers, surface cleaners, beauty care products, dish care products, diapers, feminine protection articles, and plastic films for garbage bags. Such malodor control technologies do not unduely interfere with the scent of the perfumed or unperfumed situs that is treated with the malodor control technology. | 2016-03-31 |
20160089465 | FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME - The present invention relates to freshening compositions and devices comprising same that comprise a composition comprising malodor reduction compositions and methods of making and using such compositions. Such malodor control technologies do not unduely interfere with the scent of the perfumed or unperfumed situs that is treated with the malodor control technology. | 2016-03-31 |
20160089466 | MODULAR MULTIFUNCTION FRAGRANCE EMITTER - An apparatus for producing a fragrance from a solid fragrance carrier is presented. The apparatus includes a heating element; a base positionable adjacent the heating element, the base having an upper end and a lower end; and a retainer member operable to contain the solid fragrance carrier and positionable adjacent the upper end of the base. | 2016-03-31 |
20160089467 | VOLATILE SUBSTANCES EVAPORATION DEVICE - A volatile substances evaporation device comprises a body ( | 2016-03-31 |
20160089468 | COATING PROVIDING MODULATED RELEASE OF VOLATILE COMPOSITIONS - Described are modulating coatings that are configured to provide an improved release profile of a volatile composition from a base material, wherein the modulating coating includes a barrier substance that is configured to hinder a release of the volatile composition through the modulating coating, and a hygroscopic substance that is configured to facilitate the release of the volatile composition through the modulating coating. | 2016-03-31 |
20160089469 | HIGH-COVERAGE, LOW ODER MALODOR COUNTERACTANT COMPOUNDS AND METHODS OF USE - A composition containing a malodor counteracting compound and a method for using the compound for counteracting a malodor in air space or a substrate is provided. | 2016-03-31 |
20160089470 | Purifier - Described is an ion air purifier. The ion air purifier includes a collector module ( | 2016-03-31 |
20160089471 | SHEET FOR CUTANEOUS APPLICATION CONTAINING VITAMIN E OR AN ESTER THEREOF - Sheet for cutaneous application comprising a support layer made of loosely woven fabric embedded in a layer of silicone elastomer incorporating vitamin E or an ester thereof, wherein the layer of silicone elastomer has a thickness less than or equal to 2.0 mm and the silicone elastomer contains an elasticity modifier consisting of a triglyceride of saturated C | 2016-03-31 |
20160089472 | HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions. | 2016-03-31 |
20160089473 | Transdermal Delivery System - The present invention provides a system comprising: (i) a layer containing a nitrite; and (ii) a hydrogel that contains hydrogen ions; wherein the layer containing a nitrite and/or the hydrogel comprises a pharmaceutically active agent. The invention also provides the use of a system of the invention in medicine, and in the treatment of pain. | 2016-03-31 |
20160089474 | Collagen Sponge - Provided is a collagen sponge which has compressive strength (stress) equivalent to that of a tissue into which the collagen sponge is to be implanted, has no unevenness in structure and stress, and has a pore structure for allowing cells to infiltrate thereinto. The collagen sponge is obtained by subjecting a collagen dispersion, a collagen solution, or a mixture thereof having a collagen concentration of 50 mg/ml or more to freeze-drying and insolubilization treatment thereafter. The collagen sponge thus obtained has a stress of from 10 kPa to 30 kPa when loaded with 10% strain, has in its surface and inside a pore structure having a mean pore diameter ranging from 50 μm to 400 μm, and has a pore diameter standard deviation equal to or less than 80% of the mean pore diameter. | 2016-03-31 |
20160089475 | HYALURONIC ACID-COLLAGEN MATRICES FOR DERMAL FILLING AND VOLUMIZING APPLICATIONS - Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen. | 2016-03-31 |
20160089476 | POLYMER-TISSUE HYBRID BIOMATERIALS AND METHODS OF MAKING AND USING SAME - Provided are hybrid biomaterials comprising one or more layers of cross-linked poly(propylene fumarate) and/or cross-linked copolymer comprising a plurality of cross-linked propylene fumarate moieties. The layers may further comprise a plurality of microparticles, a plurality of micropores, or both a plurality of microparticles and a plurality of micropores encapsulated within the cross-linked poly(propylene fumarate) and/or cross-linked copolymer comprising a plurality of cross-linked propylene fumarate moieties. One of the layers is disposed on a compliant matrix dense tissue substrate (e.g., a pericardium tissue substrate). The hybrid biomaterials can be used, for example, in method of repairing tissue defects. | 2016-03-31 |
20160089477 | POROUS FOAMS DERIVED FROM EXTRACELLULAR MATRIX, POROUS FOAM ECM MEDICAL DEVICES, AND METHODS OF USE AND MAKING THEREOF - The invention disclosed herein is directed to a porous wound healing foam composition that is made from an extracellular matrix of a mammal, method of making, and method of using. | 2016-03-31 |
20160089478 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO - The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. In certain embodiments, compounds disclosed herein are useful for managing obesity and diabetes or other metabolic syndromes by modulation of brown fat. | 2016-03-31 |
20160089479 | ELECTRODEPOSITION COATING FOR MEDICAL DEVICES - The present disclosure relates generally to coating medical devices. In particular, the present disclosure provides materials and methods for coating a portion of a balloon catheter with a pharmaceutical agent using electrodeposition techniques. Although angioplasty and stenting can be effective methods for treating vascular occlusions, restenosis remains a pervasiveness problem. Therefore, coating portions of a balloon catheter with a pharmaceutical agent that inhibits restenosis can reduce the likelihood of restenosis. | 2016-03-31 |
20160089480 | LUBRICIOUS MEDICAL DEVICE ELEMENTS - Embodiments of the invention include medical device elements formed from polymers with lubricious properties. In an embodiment, a method of forming a medical device element is included. The method can include mixing a first polymeric component and a second polymeric component to form a polymer mixture. The method can further include forming the polymer mixture into the medical device element. The method can also include treating the polymer mixture with at least one of an acid or a base. In an embodiment, a medical device is included. The medical device can include a lubricious element, the lubricious element comprising a mixture of a first polymeric component and a second polymeric component. The second polymeric component can include a polymer that is treated with at least one of an acid or a base after formation of the element. Other embodiments are also included herein. | 2016-03-31 |
20160089481 | MEDICAL DEVICE HAVING A SURFACE COMPRISING GALLIUM OXIDE - A medical device intended for contact with living tissue comprises a substrate having a surface, which surface comprises a layer comprising gallium oxide. A layer comprising a gallium oxide has been shown to inhibit biofilm formation on the surface of the medical device, which may reduce the risk for infection e.g. around a dental implant. A method of producing the medical device comprises: a) providing a substrate having a surface; and applying a gallium compound onto said surface to form a layer, preferably using a thin film deposition technique. | 2016-03-31 |
20160089482 | CATHETER-BASED HEART SUPPORT SYSTEM AND METHOD OF IMPLANTING THEREOF - A device for circulatory support of the heart with holding means implanted intracardially in the left or right ventricular outflow of the heart by catheter, using an endovascular method, through a femoral access or a percutaneous transventricular, transseptal, transapical or transvenous access, the holding means comprises anchoring means fixed in the subcommissural triangle underneath the aortic valve and the pulmonary valve, in the flow direction of the blood on the ventricular side of the aortic valve and the pulmonary valve, a pump fixed in the holding means by a catheter, using an endovascular method, through a femoral access or a percutaneous transventricular, transseptal, transapical or transvenous access, the pump can be inserted releasably into the holding means after the holding means has been fixed by the anchoring means in the subcommissural triangles underneath the aortic valve and the pulmonary valve, or is connected to the collapsible and expandable anchoring means. | 2016-03-31 |
20160089483 | VENTRICULAR ASSIST DEVICE CONTROLLER WITH INTEGRATED POWER SOURCE - An extra-corporeal controller unit for an implantable ventricular assist device (VAD) includes control circuitry integrated with a rechargeable power source without including any power cables between the control circuitry and the rechargeable power source. The rechargeable power source includes two or more rechargeable batteries configured in respective battery modules. The battery modules are configured for removable installation in a housing of the controller unit. Mating power connectors are integrated in the battery modules and the housing. The mating connectors are configured to couple each battery to the control circuitry whenever the respective battery module containing the battery is installed in the housing. An energy storage unit may be permanently included in the controller unit and configured to remain fully charged and provide power to the VAD when the battery modules are removed. | 2016-03-31 |
20160089484 | Pressure Output Device For Extracorporeal Hemodialysis Machine - A pressure output device (POD) assembly for sensing fluid pressure in a fluid processing system, is provided. This POD assembly includes a shell defining a shell interior, and a movable diaphragm disposed in the shell interior and separating the shell interior into a flow-through chamber and a pressure sensing side. A sensor port is in fluid communication with the pressure sensing side. An inlet port and an outlet port are in fluid communication with the flow-through chamber. The inlet port and the outlet port define an inlet and an outlet, respectively, of a flow-through channel that passes through the flow-through chamber. A boss protrudes from the interior wall of the shell and extends into the flow-through channel to prevent occlusion of flow under different pressure conditions within the flow-through chamber. | 2016-03-31 |
20160089485 | UNIVERSAL PORTABLE MACHINE FOR ONLINE HEMODIAFILTRATION USING REGENERATED DIALYSATE - Manifolds suitable for use in hemodialysis, hemofiltration, hemodiafiltration, and peritoneal dialysis are provided. One or more of the manifolds can include a manifold body and an external tube. The manifold body can include at least one conduit including a first conduit and at least one port including a first port in fluid communication with the first conduit. The external tube can be in fluid communication with the first port and can include a main segment, a first branch segment, and a second branch segment containing at least one bacterial filter. The first branch segment and/or second branch segment can include at least one flow restrictor. Dialysis machines, systems, and kits including one or more such manifold are also provided, as are methods of performing hemodiafiltration using such manifolds. | 2016-03-31 |
20160089486 | SYSTEMS AND METHODS FOR CONTROLLING THE RETURN PHASE OF A BLOOD SEPARATOIN PROCEDURE - A method is provided for controlling the return phase of a blood separation procedure having a draw phase in which blood is drawn through an access or donor line, is separated, and a fluid, such as a cellular concentrate, is flowed into a reservoir, and a return phase in which fluid is flowed from the reservoir through the donor line. The method comprises flowing fluid from the reservoir through the donor line in a steady state return; monitoring the donor line for the presence of air; and, upon detecting air in the donor line, determining the amount of fluid remaining in the reservoir. Then, either i) the donor line is purged, if the amount of fluid remaining in the reservoir exceeds a predetermined amount, and the steady state return of fluid from the reservoir through the donor line is resumed; or ii) if the amount of fluid remaining in the reservoir does not exceed the predetermined amount, the return phase is ended by terminating the flow of fluid from the reservoir through the donor line. | 2016-03-31 |
20160089487 | Methods and Devices for Controlling Biologic Microenvironments - A microenvironment of a biological body is controlled, and more particularly, is measured, changed, and monitored with respect to temperature, pH level, moisture and other tissue parameters of a region of the body while, optionally, administering a therapeutic agent to that region. | 2016-03-31 |
20160089488 | Gelatin bowel prep with syringe for colonoscopy - A purgative product is provided which includes a gelatinous purgative and a dispenser for dispensing the gelatinous purgative. The dispenser includes a container with an open end and an opening on the opposite end. A plunger and sealing element can be inserted into the container, such that when the plunger is pushed towards the opening in the container, the gelatinous purgative between the sealing element and the opening of the container is pushed towards and out of the opening for ingestion by a user. | 2016-03-31 |
20160089489 | MEDICAL IMAGING FACILITY AND METHOD FOR CONTROL OF A CONTRAST AGENT INJECTOR INTEGRATED WITHIN A MEDICAL IMAGING FACILITY - A medical imaging facility that has a signal detection unit with a patient accommodation area that accommodates a patient for a medical imaging investigation. The patient accommodation area is at least partially surrounded by the signal detection unit, and the medical imaging facility has a contrast agent injector that is integrated within the medical imaging facility. | 2016-03-31 |
20160089490 | DRUG DELIVERY DEVICE INCLUDING ELECTROLYTIC PUMP - Systems and methods are provided for a drug delivery device and use of the device for drug delivery. In various aspects, the drug delivery device combines a “solid drug in reservoir” (SDR) system with an electrolytic pump. In various aspects an improved electrolytic pump is provided including, in particular, an improved electrolytic pump for use with a drug delivery device, for example an implantable drug delivery device. A catalytic reformer can be incorporated in a periodically pulsed electrolytic pump to provide stable pumping performance and reduced actuation cycle. | 2016-03-31 |